We conducted a multicentre test negative case control study to estimate the 2013–14 influenza vaccine effectiveness (IVE) against hospitalised laboratory confirmed influenza in 12 hospitals in France, Italy and Spain. We included all ≥18 years hospitalised patients targeted by local influenza vaccination campaign reporting an influenza-like illness within 7 days before admission. We defined as cases patients RT-PCR positive for influenza and as controls those negative for all influenza virus. We used a logistic regression to calculate IVE adjusted for country, month of onset, chronic diseases and age. We included 104 A(H1N1)pdm09, 157 A(H3N2) cases and 585 controls. The adjusted IVE was 42.8% (95%CI: 6.3;65;0) against A(H1N1)pdm09. It was respectively 61.4% (95%CI: −1.9;85.4), 39.4% (95%CI: −32.2;72.2) and 19.7% (95%CI:-148.1;74.0) among patients aged 18–64, 65–79 and ≥80 years. The adjusted IVE against A(H3N2) was 38.1% (95%CI: 8.3;58.2) overall. It was respectively 7.8% (95%CI: −145.3;65.4), 25.6% (95%CI: −36.0;59.2) and 55.2% (95%CI: 15.4;76.3) among patients aged 18–64, 65–79 and ≥80 years. These results suggest a moderate and age varying effectiveness of the 2013–14 influenza vaccine to prevent hospitalised laboratory-confirmed influenza. While vaccination remains the most effective prevention measure, developing more immunogenic influenza vaccines is needed to prevent severe outcomes among target groups.

Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013–14: Results from the InNHOVE network

Iacoviello L.;
2016-01-01

Abstract

We conducted a multicentre test negative case control study to estimate the 2013–14 influenza vaccine effectiveness (IVE) against hospitalised laboratory confirmed influenza in 12 hospitals in France, Italy and Spain. We included all ≥18 years hospitalised patients targeted by local influenza vaccination campaign reporting an influenza-like illness within 7 days before admission. We defined as cases patients RT-PCR positive for influenza and as controls those negative for all influenza virus. We used a logistic regression to calculate IVE adjusted for country, month of onset, chronic diseases and age. We included 104 A(H1N1)pdm09, 157 A(H3N2) cases and 585 controls. The adjusted IVE was 42.8% (95%CI: 6.3;65;0) against A(H1N1)pdm09. It was respectively 61.4% (95%CI: −1.9;85.4), 39.4% (95%CI: −32.2;72.2) and 19.7% (95%CI:-148.1;74.0) among patients aged 18–64, 65–79 and ≥80 years. The adjusted IVE against A(H3N2) was 38.1% (95%CI: 8.3;58.2) overall. It was respectively 7.8% (95%CI: −145.3;65.4), 25.6% (95%CI: −36.0;59.2) and 55.2% (95%CI: 15.4;76.3) among patients aged 18–64, 65–79 and ≥80 years. These results suggest a moderate and age varying effectiveness of the 2013–14 influenza vaccine to prevent hospitalised laboratory-confirmed influenza. While vaccination remains the most effective prevention measure, developing more immunogenic influenza vaccines is needed to prevent severe outcomes among target groups.
2016
case control studies; hospital; Influenza; Influenza vaccine; multicentre studies
Rondy, M.; Castilla, J.; Launay, O.; Costanzo, S.; Ezpeleta, C.; Galtier, F.; de Gaetano Donati, K.; Moren, A.; Beristain, X.; Chamorro, J.; Gabari, M.; Artajo, P.; Lameiro, F.; Barrado, L.; Ortega, M.; Torres, M.; Garcia Irure, J. J.; Irisarri, F.; Garcia Cenoz, M.; Guevara, M.; Casado, I.; Diaz, J.; Martinez-Baz, I.; Castilla, J.; Lenzi, N.; Lesieur, Z.; Bonmarin, I.; Merle, C.; Foulongne, V.; Letois, F.; Driss, V.; Geraud, P.; Bourdin, A.; Landreau, L.; Konate, A.; Corne, P.; Sebbane, M.; Klouche, K.; Leglise, M. -S.; Loulergue, P.; Kanaan, R.; Dumas, F.; Krivine, A.; Moncilovic, S.; Ali, N.; Duval, X.; Costa, Y.; Ait Naman, R.; Yazdapanah, Y.; Caseris, M.; Dournon, N.; Papo, T.; Dossier, A.; Becheur, H.; Pelletier, A. -L.; Mal, M.; Marceau, A.; Aubier, M.; Bories, R.; Casalino, E.; Choquet, C.; Houhou, N.; Vanhems, P.; Regis, C.; Jouneau, S.; Laine, F.; Tattevin, P.; Beuzit, L.; Thebault, E.; Fey, S.; Lagathu et Sophie Cha, G.; Postil, D.; Alcolea, S.; Rogez, S.; Valette, M.; Lina, B.; de Gaetano Donati, K.; Cauda, R.; Taccari, F.; Santangelo, R.; Perlasca, F.; Fichera, G.; Dara, M.; Costanzo, S.; Iacoviello, L.; Olivieri, M.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2130124
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 11
social impact